In April, we added 92 citations in DIDB, including 44 in vitro (with 22 articles published in Apr. 2022) and 48 in vivo articles (with 36 articles published in Apr. 2022).
Four recently approved NDAs/BLAs were also added with the following 3 NDAs: utetium Lu-177 vipivotide tetraxetan (PLUVICTO), mitapivat (PYRUKYND), pacritinib (VONJO), and the following BLA: nivolumab and relatlimab (OPDUALAG).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.